U.S. Software Stock News

Federal Realty Investment Trust recently reported mixed third-quarter 2025 results, advanced several major redevelopments at Bala Cynwyd, Hoboken and Santana Row, acquired the Village Pointe lifestyle center in Omaha, and appointed Joseph D. Fisher to its Board of Trustees effective January 1, 2026. Together, these moves highlight Federal Realty’s push to expand its footprint in high-traffic retail locations while balancing redevelopment spending with near-term earnings pressure. Next, we’ll...

Penguin Solutions (PENG) just expanded its SMART DDR5 lineup with new 64GB DDR5 6400 ECC CSODIMM modules, a targeted move at high performance industrial, edge, telecom, and networking workloads. See our latest analysis for Penguin Solutions. The new DDR5 launch comes as Penguin Solutions shares trade at $21.83, with a solid year to date share price return suggesting early momentum, even though the 1 year total shareholder return and the 3 year total shareholder return point to a steadier,...

StandardAero (SARO) just rolled out a fresh catalyst for its stock, authorizing a share repurchase program of up to $450 million, a clear signal about how management views long term value. See our latest analysis for StandardAero. Those moves come after StandardAero’s October 2024 IPO and a string of growth focused updates, with the latest buyback coinciding with a 12.1% year to date share price return and a 7.4% one year total shareholder return. This suggests momentum is quietly...

Kontoor Brands (KTB) has had a rough stretch lately, with the stock down about 20% this year and roughly 21% over the past year, despite solid double digit earnings growth. See our latest analysis for Kontoor Brands. That drop in the 1 year share price return, and the recent slide from a 7 day share price return of minus 9.72 percent to today’s 68.18 dollars, jars with Kontoor’s strong multi year total shareholder returns. This suggests sentiment has cooled even as the long term story stays...

Earlier this month, Cal-Maine Foods announced that Johnathan Zoeller, a seasoned financial and corporate accounting executive with over 25 years of experience and most recently Westlake Corporation’s Vice President, Treasurer and Head of Investor Relations, has joined the company as Chief Financial Officer, Prepared Foods. This appointment comes as Cal-Maine Foods is viewed as a leading cash-producing player in packaged foods, with strong free cash flow supporting both investment and...

Evergy (EVRG) has quietly pulled back about 5% over the past month even though the stock is still up roughly 23% over the past year, which sets up an interesting valuation check. See our latest analysis for Evergy. With the share price now around $73.37, that recent 30 day share price pullback sits against a much stronger year to date gain and a solid multi year total shareholder return profile. This suggests momentum has cooled a bit, but the longer term story is still intact. If Evergy’s...

Taysha Gene Therapies recently hit a 52-week high after Goldman Sachs upgraded its rating and highlighted progress of TSHA-102 into Phase 3 development, while Citizens also raised its outlook following the finalization of plans for the REVEAL clinical trial. This convergence of analyst optimism around TSHA-102’s late-stage pathway underscores how regulatory clarity and clinical momentum can rapidly reshape perceptions of a pre-revenue gene therapy company. We’ll now explore how Goldman...

Earlier this year, Extreme Networks highlighted its move from a hardware-centric model toward Platform ONE, a cloud-driven, subscription-based networking platform that is expanding its recurring and deferred revenue base. This shift is gaining traction with analysts, who point to growing adoption of cloud and SaaS offerings and ongoing campus network and WiFi-7 upgrade cycles as key drivers of the company’s evolving business mix. We’ll now examine how Extreme Networks’ push into a recurring,...

Harley-Davidson (HOG) has been grinding through a rough stretch, with the stock sliding about 25% over the past 3 months and roughly 30% over the past year. See our latest analysis for Harley-Davidson. That slide is not just a bad week. It reflects a longer stretch of fading momentum, with the latest $22.35 share price sitting well below recent levels and a 1 year total shareholder return of roughly negative 30% signaling that investors are still cautious about Harley’s earnings trajectory...

Pennant Group (PNTG) just picked up fresh Wall Street attention, with William Blair’s Ryan Daniels initiating coverage at a buy rating, a move that often nudges new investors to revisit the story. See our latest analysis for Pennant Group. The upbeat call lands after a strong run. Pennant’s roughly 17% 1 month share price return and a powerful 3 year total shareholder return signal that momentum is firmly building, despite a still muted 1 year total shareholder return. If this kind of renewed...

In late November, Vistra completed its purchase of seven natural gas plants from Lotus Infrastructure Partners, announced plans for two new gas units in West Texas, and received an S&P Global credit upgrade to BBB-, reflecting improved balance sheet strength after a nuclear power sales deal and expanded generation footprint. KeyBanc’s recent initiation of coverage with a positive view on Vistra’s scale, diversified generation mix, and cash flow highlights how the company’s growing mix of...

Digital Asset, together with a consortium of major financial institutions including Virtu Financial, recently completed a second set of onchain U.S. Treasury financing transactions on the Canton Network, progressing efforts to build always-on capital markets infrastructure. This collaboration highlights Virtu’s role in advancing onchain liquidity and real-time collateral reuse, aligning its trading expertise with emerging blockchain-based market structures. We’ll now explore how Virtu’s...

PTC Therapeutics (PTCT) has quietly become one of this year’s stronger rare disease stories, with the stock climbing about 64% year to date and nearly doubling over the past 3 years. See our latest analysis for PTC Therapeutics. That kind of move is not just noise, with a 23.49% 3 month share price return and a 95.95% 3 year total shareholder return suggesting momentum in the rare disease story is still building. If PTCT’s run has you rethinking your exposure to healthcare innovators, it...

Ross Stores (ROST) just posted another quarter of solid momentum, with higher sales, 90 new stores, and a new distribution center that together signal management is still pressing its long term expansion strategy. See our latest analysis for Ross Stores. The strong operations story seems to be feeding straight into sentiment, with roughly 12% 1 month share price return and a 66% 3 year total shareholder return suggesting momentum is still building rather than fading. If Ross’s run has you...

SELLAS Life Sciences Group recently reported Phase 2 data showing that its CDK9 inhibitor SLS009, combined with azacitidine and venetoclax, achieved a 46% overall response rate and extended median survival in heavily pretreated relapsed or refractory AML-MR patients, with no dose-limiting toxicities or treatment-related deaths observed. An especially important finding was the strong activity in patients with high-risk ASXL1 and TP53 mutations and in those with only one prior line of therapy,...

Everus Construction Group (ECG) just saw Director Helena Hernandez add 250 shares to her stake, extending a year long streak of insider buying with no selling, a pattern investors tend to watch closely. See our latest analysis for Everus Construction Group. That steady drumbeat of insider buying comes as Everus Construction Group’s share price has climbed to $101.21, with a strong 90 day share price return of 28.65 percent and a 1 year total shareholder return of 47.11 percent, pointing to...

Trade Desk (TTD) is back in the spotlight after a steep share price slide, with investors trying to reconcile short term pressure from higher costs and tougher competition with its long term connected TV and retail media ambitions. See our latest analysis for Trade Desk. The latest move takes Trade Desk’s 30 day share price return to a steep negative 16.24%, compounding a year to date share price loss of 68.56% and a 12 month total shareholder return of negative 72.28%. This indicates clearly...

McCormick (MKC) has quietly underperformed the broader market over the past year, even as its revenue and profit kept growing. That gap between fundamentals and share price is exactly what makes the stock interesting now. See our latest analysis for McCormick. After sliding earlier in the year, McCormick’s recent 1 week share price return of 3.94 percent suggests sentiment may be stabilizing, even though the 1 year total shareholder return remains a weak negative. If that shift in momentum...

If you are wondering whether Exact Sciences at around $101 a share is still a smart buy or if the easy money has already been made, you are not alone and that is exactly what we are going to unpack. The stock has climbed 50.2% over the last month and is up 78.1% year to date, while still carrying a 127.2% gain over 3 years despite being 25.5% lower than 5 years ago, a rollercoaster that clearly signals shifting views on its growth potential and risk. Much of that renewed enthusiasm has been...

Ciena (CIEN) just put some numbers behind the excitement, issuing upbeat revenue guidance for the first quarter and full fiscal 2026 that leans on rising Cloud and AI network demand. See our latest analysis for Ciena. The upbeat guidance has supercharged sentiment, with Ciena’s share price jumping 9.25% in the last session and delivering a 90 day share price return of 84.62%, while its 1 year total shareholder return of 186.76% and 3 year total shareholder return of 399.42% show that this...

Rhythm Pharmaceuticals recently announced positive preliminary data from an exploratory Phase 2 trial of setmelanotide in Prader-Willi syndrome, reporting reductions in BMI and hyperphagia and indicating plans to advance to a Phase 3 registrational study. The company is also extending its Prader-Willi program with a Phase 1, Part D study of weekly MC4R agonist RM-718, signaling a broader, multi-asset approach to this rare obesity indication. Next, we’ll examine how setmelanotide’s...

Warner Music Group (WMG) just handed the creative keys to longtime A&R heavyweight Craig Kallman, naming him Chief Music Officer and tasking him with shaping artist development across the entire global roster. See our latest analysis for Warner Music Group. The appointment of Kallman as Chief Music Officer lands at a tricky market moment, with Warner Music Group’s 1 month share price return of -8.45 percent and 1 year total shareholder return of -12.85 percent pointing to fading momentum...

AngloGold Ashanti (NYSE:AU) heads into its Resourcing Tomorrow conference appearance with a timely backdrop, a 20% jump in gold production and reaffirmed multi year output guidance that puts the Sukari acquisition firmly in focus for investors. See our latest analysis for AngloGold Ashanti. That production jump and confident guidance seem to be feeding into sentiment, with the share price up 7.75% over the past month and a powerful 251.27% year to date share price return. The 3 year total...

Ferrari (RACE) has quietly slipped about 13% over the past month and roughly 23% in the past 3 months, even as revenue and net income keep growing at mid single digit rates. See our latest analysis for Ferrari. Zooming out, the recent 1 month and 3 month share price pullback contrasts with a still strong 3 year total shareholder return. This suggests momentum has cooled, but the longer term Ferrari story remains intact. If Ferrari’s recent slide has you reassessing the auto space, it could be...